Dancann Pharma manufactures medical cannabis and develops novel cannabinoid therapeutics for a broad range of diseases.
Dancann Pharma has raised $315K in total funding. The most recent round was Post-IPO Debt. The last funding was announced in July 2025.
Dancann Pharma's investors include Nordic Growth.
Dancann Pharma is headquartered in Ansager, Denmark.
Dancann Pharma manufactures medical cannabis and develops novel cannabinoid therapeutics for a broad range of diseases.
Dancann Pharma is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dancann Pharma — Funding & Investors." VCBacked, July 9, 2025, https://www.vcbacked.co/company/dancann-pharma. Accessed November 15, 2026.
VCBacked. (2025). Dancann Pharma — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/dancann-pharma
{{cite web |title=Dancann Pharma — Funding & Investors |url=https://www.vcbacked.co/company/dancann-pharma |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Dancann Pharma? Request a listing update